Companies Dominating the Prils Market
- Teva Pharmaceuticals Industries Ltd.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Boehringer Ingelheim International GmbH
- Sun Pharmaceuticals Industries Ltd.
- Pfizer Inc.
- Mylan N.V
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- Manus Aktteva Biopharma LLP
- Canagen Pharmaceuticals Inc.
- Lupin Limited
Browse Key Market Insights with Data Illustration:
In the News
- Lupin Limited entered into a contract with Medis for Lupin’s orphan drug NaMuscla (mexiletine). Further, for the symptomatic management of people with non-dystrophic myotonic (NDM) diseases, Medis will market NaMuscla in Central and Eastern European nations.
- Novartis AG collaborated with Dr. Reddy's Laboratories which is exclusive for certain of its well-known medications, such as the Voveran range, the Calcium range, and Methergine. Further, the agreement aims to increase patient’s access to these medications beyond present geographic boundaries.
